Joint Venture Deals in Pharmaceuticals and Biotechnology 2016-2026
Track JV activity across pharma and biotech with real-world examples, financial terms, and partnering trends—includes access to contract documents where available.
Unlock Strategic Growth Through Joint Ventures: Models, Partners, and Financials Driving Biopharma Expansion
The Joint Venture Deals in Pharmaceuticals and Biotechnology report offers an in-depth analysis of strategic joint ventures in the biopharma sector. This comprehensive resource details how companies collaborate through joint ventures to accelerate innovation, enter new markets, and share development risks. Covering agreements announced between 2016 and 2026, the report provides valuable insights into deal structures, financial terms, and partnership strategies.
Free report sample
Key Features & Benefits
✔ Comprehensive Coverage
Access a detailed compilation of joint venture deals, providing a broad perspective on industry trends.
✔ In-Depth Deal Analysis
Examine the structures and financial terms of joint ventures, including ownership distributions, investment amounts, and governance arrangements.
✔ Financial Benchmarking
Analyze disclosed financial terms to understand investment scales and expected returns, aiding in the assessment of fair market values.
✔ Access to Actual Contract Documents
Benefit from direct links to online copies of actual joint venture contracts filed with the Securities Exchange Commission, offering unparalleled transparency into agreement specifics.
✔ Identification of Active Dealmakers
Identify the top 25 companies most active in joint venture dealmaking, providing insights into potential partners and competitive strategies.
What’s Inside – Chapter Breakdown
Chapter 1: Introduction
An overview of the report's scope, objectives, and the significance of joint ventures in the biopharma industry.
Chapter 2: Trends in Joint Venture Dealmaking
Analysis of emerging patterns, motivations, and strategic benefits driving joint venture formations from 2016 to 2026.
Chapter 3: Structure of Joint Venture Deals
Detailed examination of common structures, governance models, and financial arrangements utilized in joint ventures.
Chapter 4: Leading Joint Venture Deals Since 2016
Profiles of significant joint venture agreements, organized by headline value, with direct links to full contract documents where available.
Chapter 5: Top 25 Most Active Joint Venture Dealmakers
Comprehensive listings of companies with the highest joint venture activity, including summaries and access to detailed deal records.
Chapter 6: Joint Venture Deal Directory
An extensive directory of joint venture deals organized by company A-Z, therapy area, technology type, and industry sector, facilitating targeted research.
Who Should Use This Report?
✅ Corporate Strategy & Business Development Teams
Evaluate joint venture models and identify optimal structures for risk-sharing and market expansion.
✅ C-Level Executives & Investors
Assess strategic alignments and capital efficiencies in joint venture formations to inform investment decisions.
✅ Legal & Transaction Advisors
Benchmark governance structures, equity distributions, and contractual terms to guide negotiations and ensure compliance.
✅ Commercial Operations Teams
Understand how joint venture partners allocate commercialization responsibilities and regional market access.
Why This Report Matters
Joint ventures serve as a strategic intermediary between mergers & acquisitions and licensing agreements, combining financial alignment with collaborative innovation. As biopharma companies seek methods to mitigate development risks, expand geographically, or achieve commercial scale, joint ventures have emerged as a powerful mechanism for long-term value creation. This report elucidates the strategies and partnerships that have shaped successful joint ventures in the industry.
Gain insights from real-world examples. Learn from industry leaders. Structure more effective partnerships.
✔ Comprehensive Coverage
Access a detailed compilation of joint venture deals, providing a broad perspective on industry trends.
✔ In-Depth Deal Analysis
Examine the structures and financial terms of joint ventures, including ownership distributions, investment amounts, and governance arrangements.
✔ Financial Benchmarking
Analyze disclosed financial terms to understand investment scales and expected returns, aiding in the assessment of fair market values.
✔ Access to Actual Contract Documents
Benefit from direct links to online copies of actual joint venture contracts filed with the Securities Exchange Commission, offering unparalleled transparency into agreement specifics.
✔ Identification of Active Dealmakers
Identify the top 25 companies most active in joint venture dealmaking, providing insights into potential partners and competitive strategies.
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in joint venture dealmaking
2.1. Introduction
2.2. Definition of joint venture deal
2.3. Trends in joint venture deals since 2016
2.3.1. Joint venture dealmaking by year, 2016-2026
2.3.2. Joint venture dealmaking by phase of development, 2016-2026
2.3.3. Joint venture dealmaking by industry sector, 2016-2026
2.3.4. Joint venture dealmaking by therapy area, 2016-2026
2.3.5. Joint venture dealmaking by technology type, 2016-2026
2.3.6. Joint venture dealmaking by most active company, 2016-2026
2.4. Reasons for entering into joint venture partnering deals
2.5. The future of joint venture deals
Chapter 3 – Overview of joint venture deal structure
3.1. Introduction
3.2. Joint venture agreement structure
Chapter 4 – Leading joint venture deals
4.1. Introduction
4.2. Top joint venture deals by value
Chapter 5 – Top 25 most active joint venture dealmakers
5.1. Introduction
5.2. Top 25 most active joint venture dealmakers
Chapter 6 – Joint venture deals including contracts directory
6.1. Introduction
6.2. Joint venture deals with contracts 2016-2026
Deal directory
Deal directory – joint venture dealmaking by companies A-Z
Deal directory – joint venture dealmaking by therapy area
Deal directory – joint venture dealmaking by technology type
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering
TABLE OF FIGURES
Figure 1: Definition of joint venture deal
Figure 2: Trends in joint venture deal announcements, 2016-2026
Figure 3: Joint venture deals signed at each phase of development, 2016-2026
Figure 4: Joint venture deals by industry sector, 2016-2026
Figure 5: Joint venture deals by therapy area, 2016-2026
Figure 6: Joint venture deals by technology type, 2016-2026
Figure 7: Top 25 most active joint venture dealmakers, 2016-2026
Figure 8: Top joint venture deals by value, 2016-2026
Figure 9: Most active joint venture dealmakers, 2016-2026
Pricing options
- $3,995: single-user (encrypted file - one user/device)
- $5,995: multi-user (encrypted file - up to 5 users/devices)
- $7,995: company (unencrypted file)
Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin PDF Reader will be provided at report delivery.
Company license files are not encrypted and can be accessed using a PDF Reader.
A full explanation of license type definitions can be found here.
Our guarantee
Price promise
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
Delivery Deadline
We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)
Latest report
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
Serious Security
We take your data and security seriously. See our privacy policy for details of how we manage your data.
Sales Support
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Biopharma Research Ltd based in County Durham, United Kingdom. We have been trading successfully online since 2012 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.
A definitive, evidence-based approach to dealmaking intelligence
Current Partnering is the industry-leading provider of pharmaceutical and biotech dealmaking intelligence, delivering a clear, structured, and evidence-based view of how partnerships are designed, negotiated, and executed in practice.
Our reports combine comprehensive deal coverage, structured data analysis, and contract-level insight, enabling a deeper understanding of how financial terms, rights, and responsibilities are defined across real-world transactions.
All reports are updated every six months, ensuring users have access to the latest deal activity, trends, and market developments.
Our methodology
Built on a continuously updated proprietary database
All analysis is underpinned by Current Agreements, our proprietary deals and alliances database, which is updated daily by our analysts as new transactions are announced globally.
Deal records are continuously reviewed and enriched as additional information becomes available, ensuring accuracy, completeness, and relevance.
Comprehensive and verifiable data sourcing
Deal data is sourced from publicly available industry disclosures, including:
-
Company press releases and announcements
-
SEC filings and equivalent regulatory disclosures
-
Company and investor presentations
-
Conference materials and company websites
All sources are captured and referenced, enabling full transparency and user verification.
Broad coverage across deal types and structures
Current Partnering provides comprehensive coverage across a wide range of deal types, including but not limited to:
-
Licensing and co-development
-
Research and collaborative R&D
-
Manufacturing, supply, and distribution
-
Commercialisation and co-promotion
-
Equity investments, joint ventures, and asset transactions
-
Options, royalties, and financing agreements
This breadth ensures a complete view of how partnerships are structured across the life sciences sector.
Structured, standardised analysis
Every deal is analysed using a consistent framework, capturing (where disclosed):
-
Financial terms — including upfront payments, milestones, and royalties
-
Rights allocation — development, manufacturing, and commercialization responsibilities
-
Deal structure — exclusivity, territorial scope, and agreement type
-
Contractual provisions — clauses defining risk, control, and value-sharing
Each deal record is fully categorised, including data fields such as:
-
Therapy area and technology type
-
Stage of development
-
Asset type and deal components
-
Geographic scope and exclusivity
-
Source documentation, including press releases and SEC filings
Financial normalisation for comparability
All financial values are standardised to USD using the exchange rate at the time of deal announcement, enabling consistent comparison of deal terms across geographies.
Contract-level insight
Where available, reports include direct access to underlying agreement documents, providing visibility into how deals are constructed in practice.
This enables users to understand:
-
How financial mechanisms are defined and triggered
-
How responsibilities are operationalised between parties
-
How flexibility, risk, and control are allocated within agreements
Designed for real-world application
Current Partnering reports are built to support business-critical decision-making, including:
-
Benchmarking comparable transactions
-
Supporting valuation and deal structuring
-
Preparing for negotiations
-
Evaluating potential partners
-
Informing internal strategy with real-world evidence
A trusted industry reference
With a long track record in the sector, Current Partnering is relied upon by leading pharmaceutical companies and emerging biotechs as a trusted source of dealmaking intelligence.
By combining proprietary data, rigorous methodology, and contract-level insight, our reports provide a reliable and authoritative foundation for understanding how deals are structured, negotiated, and valued.
